Sector News

Thwarted buyer Sanofi tries its hand at a $2.1B European generics sale

March 9, 2017
Life sciences

After losing out on two sizable deals, Sanofi CEO Olivier Brandicourt recently said his company wasn’t looking to make any big M&A moves right away. Instead, Sanofi might be looking to slim down by prepping the sale of its European generics unit, according to a new report.

The French drugmaker wants to hire advisers by the end of this month and conduct an auction after the summer for a deal estimated to be worth about €2 billion ($2.1 billion), sources told Reuters.

News of a potential sale comes after Brandicourt last month said his company is “not in a hurry to do M&A.” That represented a significant change from the company’s actions over the last year.

Sanofi made several moves during the frenzied Medivation deal fray, only to be beaten out by Pfizer with its $14 billion offer. Then, Sanofi was reportedly in talks to buy Actelion, but that company ultimately went to Johnson & Johnson for $30 billion.

Since joining Sanofi in 2015, Brandicourt has kicked off a strategic review and embarked on a strategy to build around five global business units: general medicines and emerging markets, specialty care, diabetes and cardiovascular, vaccines outfit Sanofi Pasteur and animal health group Merial.

Later, though, the drugmaker put Merial and the European generics business on the chopping block and kicked off a $1.6 billion cost-cutting effort.

Last June, the company agreed on an asset swap with Boehringer Ingelheim to send away the animal health business, valued at €11.4 billion though the deal. Sanofi picked up Boehringer’s consumer health assets in a move to bolster its offerings in a business it has targeted for growth.

Meanwhile, plenty of M&A action is taking place elsewhere around the generics industry, too. Squeezed by a wave of consolidation and price erosion, Impax Labs is currently weighing its strategic options and Germany’s Stada is in talks with three prospective buyers.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).